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The prototypic autoimmune disease, systemic lupus
erythematosus (SLE), is known to be associated with a
number of genetic polymorphisms that can affect B cell
function as well as polyclonal B cell hyperactivity. Devel-
oping an understanding of the complex nature of human
B cell activation and differentiation has permitted an
assessment of whether specific stages of B cell maturation
are affected by the tendency for polyclonal B cell activa-
tion. Moreover, the analysis of perturbations of the specific
stages of B cell maturation has generated new information
on whether abnormalities in B cell differentiation are pri-
marily involved in SLE immunopathology or, rather, are
secondary to the inflammatory environment characteristic
of subjects with this autoimmune disease. Multivariant
flow cytometric analysis has documented abnormalities in
B cell maturation that are primarily associated with lupus,
or, alternatively related to disease duration, disease activity
and concomitant medication. Together, these analyses
have provided new insights on the role of B cell over-
reactivity in SLE. Characterization of peripheral blood B
cell subsets in patients with SLE has provided unique
opportunities to identify abnormalities among pre-naïve,
transitional, pre-naïve, memory B cells and in particular
plasmablasts/plasma cells including indications for defects
in negative selection of autoreactive B cells at certain
stages. The pathogenic impact of all of these individual
disturbances remains less clear, although the findings have
served to identify SLE as associated with numerous
abnormalities in B cell development. Moreover, active SLE
is characterized by overactive T cell dependent germinal
center-like reactions that produce expanded and largely
unregulated numbers of memory B cells and plasma cells,
thereby contributing to SLE pathogenesis. Finally, an
understanding of the nature of the B cell abnormalities in
SLE has generated new targets for therapy of this disease.
The first of these, belimumab, a monoclonal antibody to
the B cell survival factor B Lymphocyte stimulator (BLyS),
has proven successful in treating patients with SLE.
Additional approaches that target specific stages of B cell
activation or differentiation are in development for treat-
ment of SLE.
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